News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Immunotherapy for brain cancer gets European PRIME status Latest addition to EMA's fast-track for cutting edge drugs
Articles Europe launches new PRIME fast-track for promising medicines Andrew McConaghie reports on a newly-launched plan to speed up access to groundbreaking new medicines in Europe.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.